PDF(Pubmed)
Abstract：
Malignant pleural effusion (MPE) is one of the common complications of lung cancer. The quality of life and prognoses for MPE patients are significantly compromised. Controlling the production of MPE can relieve patients\' symptoms, improve their quality of life, and prolong their survival. This article presents a case of advanced non-small cell lung cancer (NSCLC) with MPE and negative driver genes. The patient received envafolimab and Endostar in combination, resulting in a complete reduction of MPE and durable clinical benefits. The exploratory use of this treatment method improved the quality of life of this patient and has the potential to prolong the survival of this patient.
摘要：
恶性胸腔积液(MPE)是肺癌常见的并发症之一。MPE患者的生活质量和预后明显受损。控制MPE的产生可以缓解患者的症状，提高他们的生活质量，延长他们的生存时间.本文介绍了一例MPE和阴性驱动基因的晚期非小细胞肺癌（NSCLC）。患者接受envafolimab和Endostar联合治疗，导致MPE的完全减少和持久的临床益处。探索性使用这种治疗方法改善了该患者的生活质量，并有可能延长该患者的生存期。
